Skip to main content

Advertisement

Fig. 3 | Journal of Experimental & Clinical Cancer Research

Fig. 3

From: LINC00673 is activated by YY1 and promotes the proliferation of breast cancer cells via the miR-515-5p/MARK4/Hippo signaling pathway

Fig. 3

LINC00673 downregulation suppresses cell proliferation in vivo and is a potential therapeutic target of breast cancer. a Knockdown of LINC00673 by shRNA in MDA-MB-231 cells was confirmed by qRT-PCR. b Luminescence images of subcutaneous tumors in xenograft mouse models bearing tumors generated from MDA-MB-231 cells that were stably transfected with sh-LINC00673 or sh-NC on days 7, 14 and 30 after tumor cell injection. c Tumor volume and weight in mice treated with sh-LINC00673 or sh-NC. Tumor volume was calculated every 5 days, n = 5. d The effect of LINC00673 knockdown on tumor cell apoptosis was determined by TUNEL staining. e Protein levels of Bax, Bcl-2 and CyclinD1 in tumor tissues after the knockdown of LINC00673, as analyzed by western blotting assays. f qRT-PCR analysis of the relative LINC00673 expression in MDA-MB-231 cells transfected with ASO-LINC00673 (5 μM). The 0 μM group was used as the control. g CCK-8 assay detection of cell viability in MDA-MB-231 cells. The concentration of ASO was 5 μM. The 0 μM group was used as the control. h Representative ASO treatment tumor images, volumes and weights in the three treatment groups, n = 5. i The effect of ASO treatment on tumor cell apoptosis was determined by TUNEL staining. j Expression of Bax, Bcl-2 and Cyclin D1 in the three treatment groups, as determined by western blotting. The data are presented as the mean ± the SD of three independent experiments. ** P < 0.01 and *** P < 0.001. Scale bar: 50 μm

Back to article page